… s immunotherapy darling, shares of Dendreon Corporation ( DNDN ) have been taking a beating. Does ..... warning and a lowly $5 price target. " Dendreon is a pioneer in the cancer field ..... report. "Unfortunately, the therapy - Provenge - is highly complex with logistic and …
Shares of Dendreon ( DNDN -5.1% ) continue their descent today after Maxim initiates coverage with a sell rating, saying that Provenge faces logistic, manufacturing and competitive challenges that could impede sales growth. 1 comment!
By Theodore Cohen: Dendreon ( DNDN ) is a difficult stock to own ..... strange activities surrounding the Provenge Advisory Committee meeting of March ..... Andrew von Eschenbach disparaging Provenge (the letters, you will recall …
By Theodore Cohen: On Wednesday, May 16, Dendreon Corporation ( DNDN ) announced four presentations to be given at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, taking …
Dendreon Corporation ( DNDN ) Bank of America Merrill Lynch 2012 Health Care Conference May 16 ..... Lynch. And it’s my pleasure to introduce Greg Schiffman, CFO of Dendreon with the latest update. Thanks. Greg Schiffman Thanks very much …
Shares of Dendreon ( DNDN ) are trading lower after hours on unconfirmed rumors that the SEC has opened a probe on the company's disclosures. While the …
… their own "new" product. Dendreon received the FDA's approval to market Provenge in April of 2010 for asymptomatic ..... refractory prostate cancer. Provenge is a revolutionary, first ..... in most prostate cancers. Provenge 's approval Complete Story …
… live surgeries, and a host of other activities of importance to the urological community. Of particular interest to Dendreon ( DNDN ) investors are two papers to be presented on the corporation's lead immunotherapeutic treatment for end stage prostate …
Dendreon Corporation ( DNDN ) Deutsche Bank Securities, Inc. 37th Annual Health Care Conference ..... analyst. Next we have Greg Schiffman, the Chief Financial Officer of Dendreon . For those of you listening to the webcast and want to ask questions …
By Stephen Simpson : Volatile biotech Dendreon ( DNDN ) has been a painful lesson for some investors that there ..... expectations in mind. On Target, But The Trend Is Not Friendly Dendreon did meet expectations with first quarter sales of $82 million …